AbbVie (ABBV) had its hepatitis-C treatment by the FDA today–but that’s not necessarily bad news for Gilead Sciences (GILD). RBC’s Michael Yee explains why: As expected, FDA approved AbbVie’s HCV regimen “Viekira Pak” to treat HCV GT1 today. The price has yet to be announced but the label is available which we view as overall [...]